The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 28, 2020

Filed:

Jul. 13, 2017
Applicants:

Wisconsin Alumni Research Foundation, Madison, WI (US);

President and Fellows of Harvard College, Cambridge, MA (US);

Inventors:

Samuel H. Gellman, Madison, WI (US);

Lisa M. Johnson, Glendale, CA (US);

Alan Attie, Madison, WI (US);

Mark P. Keller, McFarland, WI (US);

Alan Saghatelian, Cambridge, MA (US);

Assignees:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 38/26 (2006.01); A61P 3/10 (2006.01); A61P 7/12 (2006.01); C07K 14/605 (2006.01); C12N 5/00 (2006.01); C12N 5/02 (2006.01); A61K 38/02 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/605 (2013.01); A61K 38/00 (2013.01);
Abstract

Described herein are peptide analogs of glucagon-like peptide 1 (GLP-1) that retain agonist activity, but are more resistant to proteolytic degradation than native GLP-1. In the analogs, at least one α-amino acid found in the native GLP-1 is replaced with a β-amino acid residue, which may or may not be cyclically constrained. Pharmaceutical compositions containing the analogs are described, as are methods to treat diabetes, and methods to make proteolytically resistant GLP-1 analogs.


Find Patent Forward Citations

Loading…